Need to Request Approval to Attend?
Start Here

Lymphoma, Leukemia & Myeloma Congress brings together a consistent community of hematology-oncology professionals who return year after year to learn, share perspectives, and advance care. The in-person setting creates space for conversation inside sessions and beyond, supporting collaboration and shared learning across disease areas.

If you need approval for CME funding, travel budget, or time away from clinic, complete the short form to receive your personalized approval toolkit:

Complete the short form below to receive:

  • A justification letter you can submit directly to your supervisor

  • A structured budget outline

  • Key talking points to support your funding request

Why Lymphoma, Leukemia & Myeloma Congress Benefits Your Institution

  • The latest clinical data in lymphoma, leukemia, CLL, and multiple myeloma
  • Practical strategies for integrating emerging therapies into practice
  • Insights into therapeutic sequencing and toxicity management
  • Data on CAR-T therapy, bispecific antibodies, antibody-drug conjugates, and novel combinations
  • Accredited continuing medical education (CME) credits

For over 25 years, Lymphoma, Leukemia & Myeloma Congress has provided clinically rigorous education designed to inform treatment decisions and improve patient outcomes.

What You’ll Bring Back to Your Team

  • Present key clinical updates during tumor board or departmental meetings
  • Share new treatment data relevant to your patient population
  • Evaluate implementation strategies for emerging therapies
  • Inform updates to internal treatment pathways and protocols
  • Strengthen quality improvement initiatives in hematologic oncology

Your participation supports evidence-based cancer care across your institution.

Why Attend Lymphoma, Leukemia & Myeloma Congress?

  • 25+ years of hematologic malignancy education
  • Focused lymphoma, leukemia, CLL and myeloma CME
  • Evidence-driven, clinically practical agenda
  • Nationally respected faculty
  • Designed for practicing hematology oncology clinicians

Lymphoma, Leukemia & Myeloma Congress remains one of the most specialized CME conferences in hematologic oncology.

Common Questions from Department Leadership

Common-Questions-from-Department-Leadership

    • How will this conference improve patient care in our practice?

      Lymphoma, Leukemia & Myeloma Congress delivers focused, evidence-based updates in lymphoma, leukemia, and multiple myeloma, with sessions designed to support clinical decision-making and implementation in real-world practice settings.

    • Is the Lymphoma, Leukemia & Myeloma Congress clinically relevant to our patient population?

      The agenda is dedicated exclusively to hematologic malignancies, ensuring direct applicability for clinicians treating lymphoma, leukemia, CLL and multiple myeloma.

    • How will knowledge gained at the Lymphoma, Leukemia & Myeloma Congress be shared with the broader team?

      Attendees can present key takeaways at tumor board, departmental meetings, or contribute to updates in treatment pathways to support system-wide improvement.

    • Is time away from clinic justified for this meeting?

      Lymphoma, Leukemia & Myeloma Congress is structured to maximize educational efficiency, providing concentrated clinical updates across four days, without unrelated content common in broader oncology conferences.

    • Are accredited CME credits provided?

      Yes. Lymphoma, Leukemia & Myeloma Congress offers accredited continuing medical education credits that support licensure and ongoing professional development.

CME Details

  • Event: Lymphoma, Leukemia & Myeloma Congress
  • Educational Focus: Lymphoma CME | Leukemia CME | Myeloma CME | CLL CME
  • Intended Audience: Hematology-Oncologists, Medical Oncologists, Advanced Practice Providers, Students/Residents/Fellows
  • CME Credits Available: 25+
  • Location: Marriott Marquis, New York City 
  • Dates: October 13-16, 2026

Unlike broader oncology meetings, this hematology conference is dedicated exclusively to hematologic malignancies.

Back to top